NeOnc Gets FDA Nod for Phase II Trial of NEO212 for Brain Cancer

NeOnc Technologies has received FDA authorization to proceed with Phase II clinical trial of NEO212, a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer. The trial follows the successful completion of the Phase I dose-escalation study, which demonstrated NEO212's safety at doses up to 810 mg daily.